Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions that involve inflammation and fibrosis and have high unmet need.
Translating novel biological insights into transformative treatments
Drug discovery and development built on a deep understanding of central fibro-inflammatory mediators and pathways
Committed to improve the quality of life of patients suffering from seriously debilitating and life-threatening diseases
Innovation & Discovery
Chemomab discovered the key role of the soluble protein CCL24 in promoting liver, skin and lung fibrosis as the driver of a fibro-inflammatory vicious cycle
Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life.
Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue.
CCL24 - a Key Player
Regulating CCL24 is key to halting fibrosis-related conditions
Chemomab discovered that the soluble protein CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment. In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix.
CM-101 Therapeutic Platform
Pioneering innovation to treat fibrosis-related diseases.
Chemomab’s lead compound, CM-101, currently in Phase 2 clinical studies, is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity.
CM-101 interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in vivo, in vitro and ex vivo studies, including experimental models of liver, skin and lung fibrosis. CM-101 is currently in Phase 2 clinical development for primary sclerosing cholangitis (PSC), a rare, potentially lethal disease of the bile ducts. It has generated encouraging biomarker data in a Phase 2a liver fibrosis trial in patients with non-alcoholic steatohepatitis (NASH) and has demonstrated activity in multiple preclinical models of systemic sclerosis (SSc).
To learn more about how CM-101 may interrupt the fibro-inflammatory vicious cycle believed to drive disease progression in PSC, see our Mechanism of Action (MOA) video at MOA video